The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Open accessAbstract
Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited treatment options. CD47 is a cell-surface molecule that promotes immune evasion by engaging signal-regulatory protein alpha (SIRPα), which serves as an inhibitory receptor on macrophages. Here, we found that CD47 is highly expressed on the surface of human SCLC cells; therefore, we investigated CD47-blocking immunotherapies as a potential approach for SCLC treatment. Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture. In a murine model, administration of CD47-blocking antibodies or targeted inactivation of the Cd47 gene markedly inhibited SCLC tumor growth. Furthermore, using comprehensive antibody arrays, we identified several possible therapeutic targets on the surface of SCLC cells. Antibodies to these targets, including CD56/neural cell adhesion molecule (NCAM), promoted phagocytosis in human SCLC cell lines that was enhanced when combined with CD47-blocking therapies. In light of recent clinical trials for CD47-blocking therapies in cancer treatment, these findings identify disruption of the CD47/SIRPα axis as a potential immunotherapeutic strategy for SCLC. This approach could enable personalized immunotherapeutic regimens in patients with SCLC and other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“SCLC exhibits a high mutation burden (49), likely due to its association with heavy tobacco use and frequent inactivation of p53 and pRB (50); therefore, it may be particularly responsive to therapies that engage the adaptive immune system.”
BackgroundThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“The dichotomy of M1 versus M2 polarization underrepresents the complexity of macrophage activation, which is dynamic and fluid with a plethora of potential activation states (30, 43).”
BackgroundMacrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Self-citationMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Self-citationShultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,728
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
Self-citationCD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Self-citationIntegrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Self-citationvan Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Self-citationRudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077
Self-citationChao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
Self-citationCD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H., Peng, H., Fu, Y.-X., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 767
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polanski, R., Burt, D. J., Simpson, K. L., Morris, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 694
Self-citationTseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 657
Self-citationSmall cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Self-citationReck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534 · cited 1×
“org Volume 126 Number 7 July 2016 Introduction Small-cell lung cancer (SCLC), which originates from neuroendocrine cells of the lung (1, 2), is one of the most lethal subtypes of cancer.”
BackgroundImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495
Self-citationPre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137345 · Cited by 475
Self-citationDaniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
Self-citationDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
Self-citationZhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330
Self-citationDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Macrophages are critical effectors of antibody therapies for cancer
Weiskopf, K., & Weissman, I. L. (2015) · mAbs · doi:10.1080/19420862.2015.1011450 · Cited by 292
Self-citationBeckman, R. A., Weiner, L. M., & Davis, H. M. (2007) · Cancer · doi:10.1002/cncr.22402 · Cited by 281
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., & Weissman, I. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222861110 · Cited by 277 · cited 1×
“In addition, calreticulin has been identified as one such prophagocytic signal and may play particular importance in the malignant conversion of myelodysplastic syndrome to acute myelogenous leukemia (45, 46).”
BackgroundSelf-citationZhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106550108 · Cited by 276
Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M., Palumbo, G. A., Introna, M., & Golay, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713732 · Cited by 272
Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
Schaffer, B. E., Park, K.-S., Yiu, G., Conklin, J. F., Lin, C., Burkhart, D. L., Karnezis, A. N., Sweet-Cordero, E. A., & Sage, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4228 · Cited by 253
Self-citationA crucial requirement for Hedgehog signaling in small cell lung cancer
Park, K.-S., Martelotto, L. G., Peifer, M., Sos, M. L., Karnezis, A. N., Mahjoub, M. R., Bernard, K., Conklin, J. F., Szczepny, A., Yuan, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2473 · Cited by 247
Self-citationPD-L1 expression in small cell neuroendocrine carcinomas
Schultheis, A. M., Scheel, A. H., Ozretić, L., George, J., Thomas, R. K., Hagemann, T., Zander, T., Wolf, J., & Buettner, R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.006 · Cited by 237
Self-citationCharacterization of the cell of origin for small cell lung cancer
Park, K.-S., Liang, M.-C., Raiser, D. M., Zamponi, R., Roach, R. R., Curtis, S. J., Walton, Z., Schaffer, B. E., Roake, C. M., Zmoos, A.-F., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.16.17012 · Cited by 227
Self-citationHatherley, D., Graham, S. C., Turner, J., Harlos, K., Stuart, D. I., & Barclay, A. N. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.026 · Cited by 215
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Brahmer, J. R., & Pardoll, D. M. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0078 · Cited by 190
Eerola, A., Soini, Y., & Pääkkö, P. K. (2000) · PubMed · Cited by 177
Specific organ metastases and survival in small cell lung cancer
NAKAZAWA, K., KURISHIMA, K., TAMURA, T., KAGOHASHI, K., ISHIKAWA, H., SATOH, H., & HIZAWA, N. (2012) · Oncology Letters · doi:10.3892/ol.2012.792 · Cited by 173
Theocharides, A. P. A., Jin, L., Cheng, P.-Y., Prasolava, T. K., Malko, A. V., Ho, J., Poeppl, A. G., van Rooijen, N., Minden, M. D., Danska, J. S., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120502 · Cited by 139
Transcriptional gene expression profiling of small cell lung cancer cells.
Pedersen, N. M., Mortensen, S., Sørensen, S. B., Pedersen, M. W., Rieneck, K., Bovin, L. F., & Poulsen, H. S. (2003) · PubMed · Cited by 117
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 95
Targets in small cell lung cancer
Teicher, B. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.014 · Cited by 79
Whiteman, K. R., Johnson, H. A., Mayo, M., Audette, C. A., Carrigan, C. N., LaBelle, A., Zukerberg, L. R., Lambert, J. M., & Lutz, R. J. (2014) · mAbs · doi:10.4161/mabs.27756 · Cited by 66
Leong, T. L., Marini, K. D., Rossello, F. J., Jayasekara, S. N., Russell, P. A., Prodanovic, Z., Kumar, B., Ganju, V., Alamgeer, M., Irving, L. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106862 · Cited by 38
Cited by
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Self-citationTumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
Metadata
- Authors
- Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., Yang, D., Seitz, G., Nguyen, T., Wu, D., Jude, K., Guerston, H., Barkal, A., Trapani, F., George, J., Poirier, J. T., Gardner, E. E., Miles, L. A., de Stanchina, E., Lofgren, S. M., Vogel, H., Winslow, M. M., Dive, C., Thomas, R. K., Rudin, C. M., van de Rijn, M., Majeti, R., Garcia, K. C., Weissman, I. L., & Sage, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-06-13
- Volume
- 126
- Issue
- 7
- Pages
- 2610-2620
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2414840542
- Cited by
- 444
- References
- 53
- FWCI
- 15.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.